MARBOCYL P 5 MG TABLETS
Land: Írland
Tungumál: enska
Heimild: HPRA (Health Products Regulatory Authority)
Vara einkenni
(SPC)
04-11-2016
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
MARBOFLOXACIN
Fáanlegur frá:
Vetoquinol UK Limited
ATC númer:
QJ01MA93
INN (Alþjóðlegt nafn):
MARBOFLOXACIN
Skammtar:
5 mg/tablet
Lyfjaform:
Tablets
Gerð lyfseðils:
POM
Meðferðarhópur:
Canine, Feline
Lækningarsvæði:
Marbofloxacin
Ábendingar:
Antibacterial
Leyfisstaða:
Authorised
Leyfisdagur:
2004-04-19
Vara einkenni
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marbocyl P 5 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
5 mg
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablet
Brown-beige spotted, circular divisible tablets.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
IN DOGS
Marbofloxacin tablet is indicated in the treatment of:
Skin and soft tissue infections (intertrigo, folliculitis, impetigo, furunculosis, cellulitis) caused by susceptible strains.
Lower and upper urinary tract infections (UTI) associated or not with prostatitis or epididymitis caused by susceptible
strains.
Respiratory tract infections caused by susceptible strains
IN CATS
Marbofloxacin tablet is indicated in the treatment of skin and soft tissue infections (wounds, abscesses, phlegmons) and upper
respiratory tract infections caused by susceptible strains.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active ingredient.
Do not use in dogs aged less than 12 months, or less than 18 months for giant breeds of dogs.
Not recommended for use in cats aged less than 16 weeks.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 20/10/2016_
_CRN 7023454_
_page number: 1_
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS
None.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Hypersensitivity (allergic) reactions may occur in treated animals.
At the therapeut
Lestu allt skjalið
